Benjamin Lockshin, MD, FAAD, outlines the clinical and practical factors driving the dominance of IL-23 inhibitors in biologic initiation, highlighting their favorable safety profile, ease of patient ...

"For many patients, having a subcutaneous induction option is an important step forward—offering the flexibility of at-home administration after proper training without compromising efficacy," said ...

Many plaque psoriasis patients that responded inadequately to an interleukin (IL)-17 inhibitor had deep and durable responses after switching to the IL-23 inhibitor risankizumab (Skyrizi), according ...

FDA authorization covers moderate-to-severe plaque psoriasis in adults and patients aged ≥12 years, expanding systemic options for adolescents. Icotrokinra is characterized as a first-in-class ...

1 One case of infusion reaction and one case of pruritus, both Grade 1 and resolved without medication. 2 One case of asymptomatic increased lipase, isolated to Day 43 post-dose (Grade 3); One case of ...

This is a syndicated post stub. Clinical Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical ...